Ruvidar Demonstrates Potential for Durable Responses in Non–Muscle Invasive Bladder Cancer

Treatment with the novel photodynamic therapy TLD-1433 activated by the laser TLC-3200 led to 6-, 12-, and 15-month complete response rates of 54%, 38%, and 37%, respectively, in patients with non–muscle invasive bladder cancer, meeting the primary and secondary end points of the phase 2 Study II trial.

Related Keywords

United States ,Canada , ,Health Canada ,International Bladder Cancer Group ,Clinical Oncology ,International Bladder Cancer ,Tld 1433 ,Novel Photodynamic Therapy ,Non Muscle Invasive Bladder Cancer ,Phase 2 Study Ii Trial Nct03945162 1 ,